Misoprostol

Generic Name
Misoprostol
Brand Names
Arthrotec, Cytotec, Mifegymiso
Drug Type
Small Molecule
Chemical Formula
C22H38O5
CAS Number
59122-46-2
Unique Ingredient Identifier
0E43V0BB57
Background

Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions. The stimulation of prostaglandin receptors in the stomach reduces gastric acid secretion, while stimulating these receptors in the uterus and cervix can increase the strength and frequency of contractions and decrease cervical tone.

Misoprostol was granted FDA approval on 27 December 1988.

Indication

Misoprostol is indicated as a tablet to reduce the risk of NSAID induced gastric ulcers but not duodenal ulcers in high risk patients. Misoprostol is also formulated in combination with diclofenac to treat symptoms of osteoarthritis or rheumatoid arthritis in patients with a high risk of developing gastric ulcers. Misoprostol is used off label for the management of miscarriages, prevention of post partum hemorrhage, and is also used alone or in combination with mifepristone in other countries for first trimester abortions.

Associated Conditions
Gastric Ulcer, Incomplete Abortion, Missed Abortion, Postpartum Haemorrhage (PPH)
Associated Therapies
Induction of cervix ripening therapy, Medically induced abortion
Clinical Trials
Related News

Carbetocin Versus Misoprostol in Cases With Placenta Previa After C.S.

First Posted Date
2014-10-28
Last Posted Date
2021-02-02
Lead Sponsor
Beni-Suef University
Target Recruit Count
200
Registration Number
NCT02277041
Locations
🇪🇬

Beni-Suef University, Cairo, Egypt

Rectal Misoprostol and Blood Loss During Abdominal Hysterectomy

Phase 3
Conditions
Blood Loss
Interventions
Drug: Placebo
Drug: Misoprostol
First Posted Date
2014-10-16
Last Posted Date
2014-10-16
Lead Sponsor
Cairo University
Target Recruit Count
220
Registration Number
NCT02265562
Locations
🇪🇬

Cairo University hospiatl, Cairo, Egypt

REgistry of MisOprostol 200 µg Vaginal dElivery System

Completed
Conditions
Induction of Labour
Interventions
Drug: Misoprostol
First Posted Date
2014-09-17
Last Posted Date
2015-09-16
Lead Sponsor
Ferring Pharmaceuticals
Target Recruit Count
106
Registration Number
NCT02242214
Locations
🇳🇱

Isala Klinieken (there may be other sites in this country), Zwolle, Netherlands

Comparison of Primary and Secondary Prevention of Postpartum Hemorrhage at the Community Level in Egypt

Phase 4
Completed
Conditions
Postpartum Hemorrhage
Interventions
Drug: Misoprostol
First Posted Date
2014-08-27
Last Posted Date
2016-02-15
Lead Sponsor
Gynuity Health Projects
Target Recruit Count
2827
Registration Number
NCT02226588
Locations
🇪🇬

Primary Health Care Units, Kafr El Dawar, El Beheira, Egypt

Misoprostol for Reduction of Blood Loss During Fibroid Surgery

Phase 4
Terminated
Conditions
Fibroids
Interventions
Drug: Placebo
Drug: Misoprostol
First Posted Date
2014-08-06
Last Posted Date
2023-09-07
Lead Sponsor
Northwestern University
Target Recruit Count
47
Registration Number
NCT02209545
Locations
🇺🇸

Northwestern University, Prentice Women's Hospital, Chicago, Illinois, United States

Misoprostol for Small Bowel Ulcers and Obscure Bleeding Due to Aspirin or Nonsteroidal Antiinflammatory Drugs

First Posted Date
2014-07-29
Last Posted Date
2018-08-14
Lead Sponsor
NHS Greater Glasgow and Clyde
Target Recruit Count
104
Registration Number
NCT02202967
Locations
🇬🇧

University Hospital Crosshouse, Kilmarnock, Scotland, United Kingdom

Oral Misoprostol Versus Vaginal Dinoprostone For Induction Of Labour: A Randomized Controlled Clinical Trial

Not Applicable
Conditions
Labour Induction
Interventions
Drug: Misoprostol
Drug: Dinoprostone
First Posted Date
2014-06-20
Last Posted Date
2014-06-20
Lead Sponsor
Ain Shams University
Target Recruit Count
342
Registration Number
NCT02168881
Locations
🇪🇬

Ain Shams Maternity hospital, Cairo, Egypt

Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study

Phase 3
Completed
Conditions
Postpartum Hemorrhage
Interventions
Drug: Misoprostol
First Posted Date
2014-06-13
Last Posted Date
2017-04-24
Lead Sponsor
Gynuity Health Projects
Target Recruit Count
635
Registration Number
NCT02163616
Locations
🇦🇷

Hospital Dr. A. Llano, Corrientes, Argentina

🇦🇷

Hospital J.R. Vidal, Corrientes, Argentina

Sub Lingual Misoprostol Before IUD Insertion in Women With Only Previous Cesarean Section

Phase 2
Completed
Conditions
IUD Insertion
Interventions
Drug: Placebo
Drug: Misoprostol
First Posted Date
2014-05-19
Last Posted Date
2015-03-18
Lead Sponsor
Ain Shams University
Target Recruit Count
124
Registration Number
NCT02141321
Locations
🇪🇬

Ain Shams University Maternity Hospital, Cairo, Egypt

Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia Using Carbetocin Versus Misoprostol

First Posted Date
2014-03-14
Last Posted Date
2017-02-15
Lead Sponsor
khalid abd aziz mohamed
Target Recruit Count
60
Registration Number
NCT02086994
Locations
🇪🇬

Benha univesity hospital, Benha, Egypt

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy